USP2-1 stabilizes MDM2 via the de-ubiquitination of its poly-ubiquitin chain, which decreases the levels of intracellular p53 in prostate cancer and cutaneous T-lymphomas [15,31,32]. Here, TP53 is linked to prostate carcinoma.